Construction of universal quantitative models for determination of roxithromycin and erythromycin ethylsuccinate in tablets from different manufacturers using near infrared reflectance spectroscopy.
Universal quantitative models using NIR reflectance spectroscopy were developed for the analysis of API contents (active pharmaceutical ingredient) in roxithromycin and erythromycin ethylsuccinate tablets from different manufacturers in China. The two quantitative models were built from 78 batches of roxithromycin samples from 18 different manufacturers with the API content range from 19.5% to 73.9%, and 66 batches erythromycin ethylsuccinate tablets from 36 manufacturers with the API content range from 28.1% to 70.9%. Three different spectrometers were used for model construction in order to have robust and universal models. The root mean square errors of cross validation (RMSECV) and the root mean square errors of prediction (RMSEP) of the model for roxithromycin tablets were 1.84% and 1.45%, respectively. The values of RMSECV and RMSEP of the model for erythromycin ethylsuccinate tablets were 2.31% and 2.16%, respectively. Based on the ICH guidelines and characteristics of NIR spectroscopy, the quantitative models were then evaluated in terms of specificity, linearity, accuracy, precision, robustness and model transferability. Our study has shown that it is feasible to build a universal quantitative model for quick analysis of pharmaceutical products from different manufacturers. Therefore, the NIR method could be used as an effective method for quick, non-destructive inspection of medicines in the distribution channels or open market.
Feng
Yan-Chun
YC
National Institute for the Control of Pharmaceutical and Biological Products, Beijing 100050, PR China.
Hu
Chang-Qin
CQ
D000900:Anti-Bacterial Agents / Q000032:analysis* / Q000737:chemistry; D002138:Calibration; D002681:China; D004348:Drug Labeling; D015643:Erythromycin Ethylsuccinate / Q000032:analysis* / Q000737:chemistry; D008956:Models, Chemical; D015203:Reproducibility of Results; D015575:Roxithromycin / Q000032:analysis* / Q000737:chemistry; D013055:Spectrophotometry, Infrared / Q000295:instrumentation / Q000379:methods*; D017550:Spectroscopy, Fourier Transform Infrared; D019265:Spectroscopy, Near-Infrared; D013607:Tablets / Q000032:analysis
D000900:Anti-Bacterial Agents; D013607:Tablets; D015643:Erythromycin Ethylsuccinate; D015575:Roxithromycin